“Drug Repurposing of Loratadine As a DNMT1 Inhibitor: Comparative Evaluation With Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells”. Precision Medicine Communications 4, no. 2 (December 30, 2024): 125–137. Accessed April 3, 2026. https://rootspress.org/journals/PMC/article/view/1083.